Craft

AcelRx Pharmaceuticals

Stock Price

$1.1

2024-03-12

Market Capitalization

$14.6 M

2024-03-12

Revenue

$28 K

FY, 2025

AcelRx Pharmaceuticals Summary

Company Summary

Overview
AcelRx Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. Its product candidates, DSUVIA (also known as DZUVEO) and ZALVISO, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings.
Type
Public
Status
Active
Founded
2005
HQ
Redwood City, CA, US | view all locations
Website
https://www.acelrx.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Vincent J. Angotti

    Vincent J. Angotti, Chief Executive Officer, Director

  • Pamela P. Palmer

    Pamela P. Palmer, Chief Medical Officer and Co-Founder, Director

  • Raffi Asadorian

    Raffi Asadorian, Chief Financial Officer

  • Badri Dasu

    Badri Dasu, Chief Engineering Officer

Operating MetricsView all

Patents (US)

25
13.6%

FY, 2019

Patents (Foreign)

27

FY, 2019

LocationsView all

1 location detected

  • Redwood City, CA HQ

    United States

    351 Galveston Dr

AcelRx Pharmaceuticals Financials

Summary Financials

Net income (Q1, 2026)
($2.6M)
Cash (Q1, 2026)
$3.8M
EBIT (Q1, 2026)
($3.9M)

Footer menu